File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection

TitleEffect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection
Authors
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2005, v. 100 n. 5, p. 1099-1103 How to Cite?
AbstractOBJECTIVE: To determine the effect of 1-yr lamivudine treatment on serum covalently closed-circular DNA (cccDNA) level. PATIENTS AND METHOD: Serum total HBV DNA and cccDNA levels at baseline, week 24, and week 52 were measured in 82 lamivudine-treated patients, 17 of whom received 1-yr placebo and acted as controls. RESULTS: There was a significant reduction in the cccDNA levels from baseline (median 3.0 × 106 copies/ml) to week 24 (33,476 copies/ml) and week 52 (48,694 copies/ml) (p < 0.001 for both). The median reduction in cccDNA level at week 24 and 52 were 2.21 and 2.12 logs, respectively, which were significantly greater than those of controls (0.31 log, p < 0.001; 0.2 log, p < 0.001, respectively). Fifteen patients (18.3%) developed YMDD mutations by week 52. Compared to patients without YMDD mutations, patients with YMDD mutations had significantly less median reduction of total HBV DNA level (4.44 vs 3.65 logs, respectively, p = 0.02) and cccDNA level (2.27 vs 1.65 logs, respectively, p = 0.016) at week 24 and significantly less median reduction of cccDNA at week 52 (2.35 vs 0.8 logs respectively, p < 0.001). CONCLUSIONS: One-year lamivudine treatment decreased serum cccDNA level by 2 logs. The chance of YMDD mutations at week 52 was related to the magnitude of viral suppression at week 24. © 2005 by Am. Coll. of Gastroenterology Published by Blackwell Publishing.
Persistent Identifierhttp://hdl.handle.net/10722/77043
ISSN
2015 Impact Factor: 10.383
2015 SCImago Journal Rankings: 3.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorSum, SSMen_HK
dc.contributor.authorYuan, HJen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:27:39Z-
dc.date.available2010-09-06T07:27:39Z-
dc.date.issued2005en_HK
dc.identifier.citationAmerican Journal Of Gastroenterology, 2005, v. 100 n. 5, p. 1099-1103en_HK
dc.identifier.issn0002-9270en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77043-
dc.description.abstractOBJECTIVE: To determine the effect of 1-yr lamivudine treatment on serum covalently closed-circular DNA (cccDNA) level. PATIENTS AND METHOD: Serum total HBV DNA and cccDNA levels at baseline, week 24, and week 52 were measured in 82 lamivudine-treated patients, 17 of whom received 1-yr placebo and acted as controls. RESULTS: There was a significant reduction in the cccDNA levels from baseline (median 3.0 × 106 copies/ml) to week 24 (33,476 copies/ml) and week 52 (48,694 copies/ml) (p < 0.001 for both). The median reduction in cccDNA level at week 24 and 52 were 2.21 and 2.12 logs, respectively, which were significantly greater than those of controls (0.31 log, p < 0.001; 0.2 log, p < 0.001, respectively). Fifteen patients (18.3%) developed YMDD mutations by week 52. Compared to patients without YMDD mutations, patients with YMDD mutations had significantly less median reduction of total HBV DNA level (4.44 vs 3.65 logs, respectively, p = 0.02) and cccDNA level (2.27 vs 1.65 logs, respectively, p = 0.016) at week 24 and significantly less median reduction of cccDNA at week 52 (2.35 vs 0.8 logs respectively, p < 0.001). CONCLUSIONS: One-year lamivudine treatment decreased serum cccDNA level by 2 logs. The chance of YMDD mutations at week 52 was related to the magnitude of viral suppression at week 24. © 2005 by Am. Coll. of Gastroenterology Published by Blackwell Publishing.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_HK
dc.relation.ispartofAmerican Journal of Gastroenterologyen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAmino Acid Motifs - drug effects - geneticsen_HK
dc.subject.meshAnti-HIV Agents - therapeutic useen_HK
dc.subject.meshAspartic Acid - drug effects - geneticsen_HK
dc.subject.meshDNA, Circular - blood - drug effectsen_HK
dc.subject.meshDNA, Viral - blood - drug effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHepatitis B virus - drug effects - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIsoleucine - geneticsen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMethionine - drug effects - geneticsen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMutation - geneticsen_HK
dc.subject.meshPlacebosen_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.subject.meshTyrosine - drug effects - geneticsen_HK
dc.subject.meshValine - geneticsen_HK
dc.subject.meshViral Loaden_HK
dc.titleEffect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9270&volume=100&issue=5&spage=1099&epage=103&date=2005&atitle=Effect+of+lamivudine+therapy+on+the+serum+covalently+closed-circular+(ccc)+DNA+of+chronic+hepatitis+B+infection.en_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH:danywong@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1572-0241.2005.41530.xen_HK
dc.identifier.pmid15842584-
dc.identifier.scopuseid_2-s2.0-19144371967en_HK
dc.identifier.hkuros101359en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-19144371967&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume100en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1099en_HK
dc.identifier.epage1103en_HK
dc.identifier.isiWOS:000228489900017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridSum, SSM=6603889128en_HK
dc.identifier.scopusauthoridYuan, HJ=7402446707en_HK
dc.identifier.scopusauthoridYuen, JCH=7102620480en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats